1,421 reports of this reaction
5.7% of all TIOTROPIUM BROMIDE INHALATION SPRAY reports
#2 most reported adverse reaction
ASTHMA is the #2 most commonly reported adverse reaction for TIOTROPIUM BROMIDE INHALATION SPRAY, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 1,421 FDA adverse event reports linking TIOTROPIUM BROMIDE INHALATION SPRAY to ASTHMA. This represents approximately 5.7% of all 25,050 adverse event reports for this drug.
Patients taking TIOTROPIUM BROMIDE INHALATION SPRAY who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among TIOTROPIUM BROMIDE INHALATION SPRAY users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for TIOTROPIUM BROMIDE INHALATION SPRAY:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 1,421 FDA reports for TIOTROPIUM BROMIDE INHALATION SPRAY. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 5.7% of all adverse event reports for TIOTROPIUM BROMIDE INHALATION SPRAY, making it one of the most commonly reported side effect.
If you experience asthma while taking TIOTROPIUM BROMIDE INHALATION SPRAY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.